AJ Pharma completes Danish vaccine business acquisition

KUALA LUMPUR: AJ Pharma Group has completed its first global vaccine business acquisition in Denmark, creating an independent vaccine production business through the governmentowned Statens Serum Institut (SSI).

In a statement yesterday, AJ Pharma said upon acquisition, the SSI has been renamed AJ Vaccines.

“The completion of this acquisition is a significant milestone in the AJ Pharma Group’s global strategy to create a stronger presence in the vaccine market across the world.

“Most significantly, AJ Vaccines complements the group’s ongoing project to establish a vaccine formulation, fill and finish facility in Malaysia through AJ Biologics Sdn Bhd,” it said AJ Vaccines Chairman Dr Tabassum Khan said the acquisition now brings the group a step closer to achieving its vision of becoming a top vaccine player globally.

“Together with our ongoing project, which is to establish a vaccine formulation, fill and finish facility in Malaysia, we are now in a prime position to achieve economic, social and humanitarian objectives for Malaysia and beyond,” he added.

The Danish acquisition will enable the AJ Pharma Group to leverage the established vaccine portfolio and manufacturing expertise that SSI has built over the years.

Alongside this, SSI’s public health image and legacy across many countries will also benefit the group largely.

Moreover, it will also strengthen the AJ Pharma Group’s on- going endeavour to establish Malaysia’s first vaccine formulation, fill and finish facility that adheres to cGMP and international accreditation standards. —